{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:37:17Z","timestamp":1793450237971,"version":"4.5.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis US LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ymthe.2026.02.020","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:23:45Z","timestamp":1771028625000},"page":"2621-2636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Reprogramming CD22 CAR-T cells in vivo using CD8-targeted mRNA-LNPs to treat hematological malignancies"],"prefix":"10.1016","volume":"34","author":[{"given":"Viktor T.","family":"Lemgart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7090-461X","authenticated-orcid":false,"given":"Andrew J.","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Kuhlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron P.","family":"Griset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Caron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharini","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sampa","family":"Maiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Monte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralston","family":"Augspurg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyoung","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Pype","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Lihoradova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Quido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fazila","family":"Nasimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Scantland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavana","family":"Girish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasika D.","family":"Kunden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garry","family":"Cuneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janina","family":"Schwarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin W.","family":"Boesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria R.","family":"Fantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik B.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald R.","family":"Shaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl C.","family":"Drummond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.02.020_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.02.020_bib2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","article-title":"Programming CAR-T cells to kill cancer","volume":"2","author":"Labanieh","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2026.02.020_bib3","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.02.020_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076300","article-title":"CAR T Cell Therapy: A Versatile Living Drug","volume":"24","author":"De Marco","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.02.020_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/frtra.2023.1238535","article-title":"Promises and challenges of a decentralized CAR T-cell manufacturing model","volume":"2","author":"Shah","year":"2023","journal-title":"Front. Transpl."},{"key":"10.1016\/j.ymthe.2026.02.020_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.02.020_bib7","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2026.02.020_bib8","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma","volume":"25","author":"Bouchkouj","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.02.020_bib9","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","article-title":"A guide to manufacturing CAR T cell therapies","volume":"53","author":"Vormittag","year":"2018","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.02.020_bib11","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jconrel.2019.12.047","article-title":"Current challenges and emerging opportunities of CAR-T cell therapies","volume":"319","author":"Abreu","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ymthe.2026.02.020_bib12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.02.020_bib13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/stem.2402","article-title":"Concise Review: Application of In Vitro Transcribed Messenger RNA for Cellular Engineering and Reprogramming: Progress and Challenges","volume":"35","author":"Steinle","year":"2017","journal-title":"Stem Cells"},{"key":"10.1016\/j.ymthe.2026.02.020_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202304378","article-title":"In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism","volume":"20","author":"Billingsley","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.ymthe.2026.02.020_bib15","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics--developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.02.020_bib16","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.ymthe.2026.02.020_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/natrevmats.2017.56","article-title":"Tools for translation: non-viral materials for therapeutic mRNA delivery","volume":"2","author":"Hajj","year":"2017","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.ymthe.2026.02.020_bib18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/gt.2017.5","article-title":"Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems","volume":"24","author":"Guan","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.02.020_bib19","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.02.020_bib20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.02.020_bib21","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.02.020_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.02.020_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.02.020_bib24","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.02.020_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.02.020_bib26","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ymthe.2026.02.020_bib27","article-title":"Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.02.020_bib28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.02.020_bib29","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1016\/j.ymthe.2021.06.004","article-title":"Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs","volume":"29","author":"Tomb\u00e1cz","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.02.020_bib30","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.02.020_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06936-1","article-title":"Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes","volume":"9","author":"Veiga","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.02.020_bib32","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.1021\/acsnano.5b02796","article-title":"Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles","volume":"9","author":"Ramishetti","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.ymthe.2026.02.020_bib33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jconrel.2018.10.015","article-title":"PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake","volume":"291","author":"Parhiz","year":"2018","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2026.02.020_bib34","article-title":"Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver","volume":"7","author":"Kim","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2026.02.020_bib35","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/mt.2015.175","article-title":"Delivery of siRNAs to Dendritic Cells Using DEC205-Targeted Lipid Nanoparticles to Inhibit Immune Responses","volume":"24","author":"Katakowski","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.02.020_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc9450","article-title":"CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy","volume":"6","author":"Rosenblum","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2026.02.020_bib37","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1021\/mp060040v","article-title":"Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation","volume":"3","author":"Hayes","year":"2006","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymthe.2026.02.020_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102518","article-title":"In situ engineering of mRNA-CAR T cells using spleen-targeted ionizable lipid nanoparticles to eliminate cancer cells","volume":"59","author":"Li","year":"2024","journal-title":"Nano Today"},{"key":"10.1016\/j.ymthe.2026.02.020_bib39","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.addr.2020.06.026","article-title":"Lipid nanoparticle technology for therapeutic gene regulation in the liver","volume":"159","author":"Witzigmann","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2026.02.020_bib40","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2016.05.059","article-title":"Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA","volume":"235","author":"Chen","year":"2016","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2026.02.020_bib41","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jconrel.2024.04.022","article-title":"Lipid nanoparticle-based strategies for extrahepatic delivery of nucleic acid therapies \u2013 challenges and opportunities","volume":"370","author":"Simonsen","year":"2024","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2026.02.020_bib42","doi-asserted-by":"crossref","first-page":"8487","DOI":"10.1038\/s41598-021-87753-3","article-title":"Proteoglycans contribute to the functional integrity of the glomerular endothelial cell surface layer and are regulated in diabetic kidney disease","volume":"11","author":"Khramova","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2026.02.020_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020597","article-title":"Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method","volume":"15","author":"Berger","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2026.02.020_bib44","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1021\/acs.nanolett.3c00304","article-title":"In Vivo RNA Delivery to Hematopoietic Stem and Progenitor Cells via Targeted Lipid Nanoparticles","volume":"23","author":"Shi","year":"2023","journal-title":"Nano Lett."},{"key":"10.1016\/j.ymthe.2026.02.020_bib45","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1038\/s41467-022-33157-4","article-title":"Payload distribution and capacity of mRNA lipid nanoparticles","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.02.020_bib46","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.02.020_bib47","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering","volume":"20","author":"Billingsley","year":"2020","journal-title":"Nano Lett."},{"key":"10.1016\/j.ymthe.2026.02.020_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.66","article-title":"Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles","volume":"2","author":"Mui","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.02.020_bib49","doi-asserted-by":"crossref","first-page":"12397","DOI":"10.1128\/JVI.01420-14","article-title":"High Frequencies of Polyfunctional CD8+ NK Cells in Chronic HIV-1 Infection Are Associated with Slower Disease Progression","volume":"88","author":"Ahmad","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.02.020_bib50","doi-asserted-by":"crossref","first-page":"55222","DOI":"10.18632\/oncotarget.10484","article-title":"Altered phenotypic and functional characteristics of CD3+CD56+ NKT-like cells in human gastric cancer","volume":"7","author":"Peng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2026.02.020_bib51","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.omtm.2020.01.012","article-title":"A High-Throughput Method for Characterizing Novel Chimeric Antigen Receptors in Jurkat Cells","volume":"16","author":"Bloemberg","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.02.020_bib52","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","article-title":"Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor","volume":"32","author":"Kochenderfer","year":"2009","journal-title":"J. Immunother."},{"key":"10.1016\/j.ymthe.2026.02.020_bib53","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22\u2013chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.02.020_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1321596","article-title":"Fine-tuning the antigen sensitivity of CAR T cells: emerging strategies and current challenges","volume":"14","author":"Harrer","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.02.020_bib55","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12964-020-00617-7","article-title":"The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy","volume":"18","author":"Liu","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ymthe.2026.02.020_bib56","article-title":"Development of CAR-T Cell Persistence in Adoptive Immunotherapy of Solid Tumors","volume":"10","author":"Fan","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2026.02.020_bib57","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1111\/ajt.13607","article-title":"Quantification of CD4+ T Cell Alloreactivity and Its Control by Regulatory T Cells Using Time-Lapse Microscopy and Immune Synapse Detection","volume":"16","author":"Juvet","year":"2016","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.ymthe.2026.02.020_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061283","article-title":"Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.02.020_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.684642","article-title":"Engineered Cytokine Signaling to Improve CAR T Cell Effector Function","volume":"12","author":"Bell","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.02.020_bib60","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/026119290903701S05","article-title":"An Immunologic Model for Rapid Vaccine Assessment\u2014A Clinical Trial in a Test Tube","volume":"37","author":"Higbee","year":"2009","journal-title":"Altern. Lab. Anim."},{"key":"10.1016\/j.ymthe.2026.02.020_bib61","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1021\/acs.accounts.1c00521","article-title":"Immunogenicity of In Vitro-Transcribed RNA","volume":"54","author":"Mu","year":"2021","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ymthe.2026.02.020_bib62","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","article-title":"A Review of Patisiran (ONPATTRO\u00ae) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis","volume":"9","author":"Urits","year":"2020","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.ymthe.2026.02.020_bib63","doi-asserted-by":"crossref","first-page":"e430","DOI":"10.1038\/bcj.2016.38","article-title":"Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice","volume":"6","author":"Liu","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ymthe.2026.02.020_bib64","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1089\/hum.2011.070","article-title":"Treatment of Advanced Leukemia in Mice with mRNA Engineered T Cells","volume":"22","author":"Barrett","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.02.020_bib65","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.02.020_bib66","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.02.020_bib67","first-page":"163","article-title":"Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharmaceut. Med."},{"key":"10.1016\/j.ymthe.2026.02.020_bib68","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jcyt.2018.11.009","article-title":"Manufacturing chimeric antigen receptor T cells: issues and challenges","volume":"21","author":"Roddie","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2026.02.020_bib69","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000971712.73401.70","article-title":"P1204: Axicabtagene Ciloleucel Vein-to-Vein Time in Trial or Real-World Settings Vs Other Car T-Cell Therapies for Relapsed\/Refractory Large B-Cell Lymphoma: A Systematic Literature Review and Meta-Analysis","volume":"7","author":"Locke","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.ymthe.2026.02.020_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.640082","article-title":"Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma","volume":"12","author":"Mart\u00ednez Bedoya","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.02.020_bib71","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11538-021-00869-5","article-title":"Modeling CAR T-Cell Therapy with Patient Preconditioning","volume":"83","author":"Owens","year":"2021","journal-title":"Bull. Math. Biol."},{"key":"10.1016\/j.ymthe.2026.02.020_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071684","article-title":"Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed\/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma","volume":"13","author":"Korell","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2026.02.020_bib73","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s43586-022-00104-y","article-title":"Nanodelivery of nucleic acids","volume":"2","author":"Mendes","year":"2022","journal-title":"Nat. Rev. Methods Primers"},{"key":"10.1016\/j.ymthe.2026.02.020_bib74","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2026.02.020_bib75","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/2277-9175.98152","article-title":"Viral and nonviral delivery systems for gene delivery","volume":"1","author":"Nayerossadat","year":"2012","journal-title":"Adv. Biomed. Res."},{"key":"10.1016\/j.ymthe.2026.02.020_bib76","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.3390\/molecules25163731","article-title":"Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology","volume":"25","author":"Zieli\u0144ska","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ymthe.2026.02.020_bib77","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40139-021-00227-z","article-title":"Toxicology of Nanoparticles in Drug Delivery","volume":"9","author":"Sharma","year":"2021","journal-title":"Curr. Pathobiol. Rep."},{"key":"10.1016\/j.ymthe.2026.02.020_bib78","first-page":"1397","article-title":"Characterization of a messenger RNA polynucleotide vaccine vector","volume":"55","author":"Conry","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2026.02.020_bib79","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.02.020_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/biom13101497","article-title":"Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing","volume":"13","author":"Youssef","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.ymthe.2026.02.020_bib81","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.02.020_bib82","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-024-01065-z","article-title":"Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients","volume":"14","author":"Mart\u00edn-Mart\u00edn","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ymthe.2026.02.020_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065688","article-title":"CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma","volume":"24","author":"Wittibschlager","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.02.020_bib84","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.02.020_bib85","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12967-022-03442-3","article-title":"Exhaustion of CAR T cells: potential causes and solutions","volume":"20","author":"Kouro","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.02.020_bib86","doi-asserted-by":"crossref","first-page":"E5859","DOI":"10.1073\/pnas.1805358115","article-title":"Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters","volume":"115","author":"McKinlay","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.02.020_bib90","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/icb.1991.58","article-title":"Preparation and characterization of a chimeric CD19 monoclonal antibody","volume":"69","author":"Zola","year":"1991","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.ymthe.2026.02.020_bib91","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4161\/mabs.1.3.8113","article-title":"Identification and characterization of fully human anti-CD22 monoclonal antibodies","volume":"1","author":"Xiao","year":"2009","journal-title":"MAbs"},{"key":"10.1016\/j.ymthe.2026.02.020_bib87","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2083466","article-title":"Development of disulfide-stabilized Fabs for targeting of antibody-directed nanotherapeutics","volume":"14","author":"Geddie","year":"2022","journal-title":"MAbs"},{"key":"10.1016\/j.ymthe.2026.02.020_bib88","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1021\/bp049840y","article-title":"Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification","volume":"21","author":"Nellis","year":"2005","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.ymthe.2026.02.020_bib89","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1021\/bp049839z","article-title":"Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis","volume":"21","author":"Nellis","year":"2005","journal-title":"Biotechnol. Prog."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626001061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626001061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:36:37Z","timestamp":1781829397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626001061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1525001626001061"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.02.020","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reprogramming CD22 CAR-T cells in vivo using CD8-targeted mRNA-LNPs to treat hematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sanofi. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}